Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, BTIG Research Analyst Says

Liquidia (NASDAQ:LQDA) had its target price boosted by equities researchers at BTIG Research from $49.00 to $50.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 44.84% from the stock’s current price.

Several other equities analysts also recently issued reports on the stock. HC Wainwright upped their price objective on shares of Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday. Zacks Research lowered shares of Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Sunday, January 18th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and an average price target of $40.56.

Liquidia Trading Up 0.4%

Shares of NASDAQ LQDA opened at $34.52 on Thursday. The stock has a market capitalization of $3.00 billion, a P/E ratio of -23.97, a PEG ratio of 0.60 and a beta of 0.52. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The business’s 50 day moving average is $37.07 and its two-hundred day moving average is $30.84. Liquidia has a 1-year low of $11.26 and a 1-year high of $46.67.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). The company had revenue of $92.02 million during the quarter. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company’s quarterly revenue was up 3072.4% on a year-over-year basis. As a group, research analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, insider Scott Moomaw sold 20,533 shares of Liquidia stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $768,550.19. Following the transaction, the insider directly owned 154,514 shares of the company’s stock, valued at $5,783,459.02. The trade was a 11.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Michael Kaseta sold 36,932 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the transaction, the chief financial officer directly owned 350,919 shares in the company, valued at approximately $13,134,898.17. The trade was a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 212,534 shares of company stock worth $7,964,719. 26.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farallon Capital Management LLC increased its position in Liquidia by 1.1% during the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after buying an additional 90,400 shares during the last quarter. Vanguard Group Inc. raised its holdings in Liquidia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after acquiring an additional 52,671 shares in the last quarter. Opaleye Management Inc. lifted its position in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares during the period. Caprock Group LLC boosted its position in shares of Liquidia by 9.3% during the 4th quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after acquiring an additional 151,832 shares in the last quarter. Finally, TCG Crossover Management LLC acquired a new stake in shares of Liquidia in the 3rd quarter valued at $38,887,000. Institutional investors own 64.54% of the company’s stock.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non‑GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).